Announced details
Regenerative medicine, life sciences, research, clinical development, commercial production, and cell product manufacturing
The device was developed with the cooperation of RORZE Life Science Co., Ltd. Details of the capital, personnel and business relationships are Not disclosed.
Lightweight design among the most compact in the industry (specific figures are Not disclosed)
The impact on results for the current fiscal year is immaterial at this time.
The company does not address Contract Value / Offering price.
References to the US FDA (Food and Drug Administration), as well as its Advanced Manufacturing and Quality by Design (QbD) initiatives
| Item | Details |
|---|---|
| Names of Products / Services Covered | CAP (Compact Automated Pipettor; product name: CAP), Foldable compact dispensing machine |
| Counterparty | RORZE Life Science Co., Ltd. |
| Relationship with the Company | The device was developed with the cooperation of RORZE Life Science Co., Ltd. Details of the capital, personnel and business relationships are Not disclosed. |
| Launch date | 11 June 2026 (sales launch; actual) |
| Applicable area | Regenerative medicine, life sciences, research, clinical development, commercial production, and cell product manufacturing |
| Location scale | Lightweight design among the most compact in the industry (specific figures are Not disclosed) |
| Impact on Business Performance | The impact on results for the current fiscal year is immaterial at this time. |
| Source | References to the US FDA (Food and Drug Administration), as well as its Advanced Manufacturing and Quality by Design (QbD) initiatives |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To meet market demand for automation, mass production and standardisation in cell product manufacturing, while reducing manufacturing costs, improving mass-production capability and scalability, and stabilising quality.